Adam Sangeorzan, MD
Foot and Ankle Surgery · Seattle, WANPI 1174865224
Payments from drug & device makers
What this record shows
This record is dominated by grants: $7,500 of the $11,659 with a category attached, or 64.3%. Arthrex accounts for 83.7% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $7,843 and has fallen 99.0% since, to $76 in 2025.
Across 29 payments — averaging $402.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$10K
- Summit Surgical Corp.$1K
- Kairos Surgical Inc$138
- Zimmer Biomet$125
- Stryker$111
- Johnson & Johnson$105
- plus $36 from 1 others
What the payments were for
- Grants$7,50064%
- Travel & lodging$7566%
- Food & beverage$8217%
- Education$2,58222%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 15 | $9,761 |
| Summit Surgical Corp. | 2 | $1,382 |
| Kairos Surgical Inc | 1 | $138 |
| Zimmer Biomet | 1 | $125 |
| Stryker | 4 | $111 |
| Johnson & Johnson | 5 | $105 |
| Bioventus LLC | 1 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Persona MC$125
- MyMobility$125
How this compares
$11,659 in reported general payments places this provider in the 85th percentile of 203 foot and ankle surgery providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 12 | $554 |
| Gabapentin | 12 | $178 |
| Ondansetron Hcl | 11 | $77 |
| Oxycodone Hcl | 23 | $56 |
Paid to pharmacies, not to this prescriber.
Other foot and ankle surgery in Seattle
- David DalstromSeattle$491K
- Adam AlbabaSeattle$46K
- Stephen BenirschkeSeattle$45K
- Kivanc AtesokSeattle$16K
- Christopher PriceSeattle$11K
- Kenneth ChinSeattle$10K
- Gregory GrantSeattle$6K
- Anthony LoSeattle$6K
- Maduwilla SilvaSeattle$6K
- Salvatore RizzoSeattle$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.